Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis

Cholangiocarcinoma (CCA) is a subtype of bile duct cancer usually diagnosed late with a low survival rate and no satisfactorily systemic treatment. Recently, regorafenib has been accepted as a second-line treatment for CCA patients. In this study, we investigated the potential signal transduction pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yu-Chan, Li, Chien-Hsiu, Chan, Ming-Hsien, Chen, Ming-Huang, Yeh, Chun-Nan, Hsiao, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023529/
https://www.ncbi.nlm.nih.gov/pubmed/35449153
http://dx.doi.org/10.1038/s41419-022-04816-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023529/
https://www.ncbi.nlm.nih.gov/pubmed/35449153
http://dx.doi.org/10.1038/s41419-022-04816-7

Ejemplares similares